Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1998049146) CYCLIN DEPENDENT KINASE (CDK)4 INHIBITORS AND THEIR USE FOR TREATING CANCER
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1998/049146 International Application No.: PCT/US1998/008602
Publication Date: 05.11.1998 International Filing Date: 28.04.1998
Chapter 2 Demand Filed: 19.11.1998
IPC:
C07D 219/06 (2006.01) ,C07D 219/08 (2006.01) ,C07D 285/24 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
219
Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
04
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
06
Oxygen atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
219
Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
04
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
08
Nitrogen atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
285
Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/-C07D283/183
15
Six-membered rings
16
Thiadiazines; Hydrogenated thiadiazines
18
1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
20
condensed with carbocyclic rings or ring systems
22
condensed with one six-membered ring
24
with oxygen atoms directly attached to the ring sulfur atom
Applicants:
THE UNITED STATES OF AMERICA, represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH [US/US]; Office of Technology Transfer Suite 325, 6011 Executive Boulevard Rockville, MD 20852-3804, US (AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BY, CA, CF, CG, CH, CI, CM, CN, CU, CY, CZ, DE, DK, EE, ES, FI, FR, GA, GB, GE, GH, GM, GN, GR, GW, HU, ID, IE, IL, IS, IT, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MC, MD, MG, MK, ML, MN, MR, MW, MX, NE, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SN, SZ, TD, TG, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW)
KELLEY, Michael, J. [US/US]; US (UsOnly)
NAKAGAWA, Kazuhiko [JP/JP]; JP (UsOnly)
DENT, Barry, Roy [NZ/NZ]; NZ (UsOnly)
Inventors:
KELLEY, Michael, J.; US
NAKAGAWA, Kazuhiko; JP
DENT, Barry, Roy; NZ
Agent:
SLATER, Stacey, C.; Klarquist, Sparkman, Campbell, Leigh & Whinston, LLP One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, OR 97204-2988, US
NOONAN, William, D.; Klarquist, Sparkman, Campbell, Leigh & Whinston, L .L.P. Suite 1600 - One World Trade Center 121 S.W. Salmon Street Portland, OR 97204, US
Priority Data:
60/044,25628.04.1997US
Title (EN) CYCLIN DEPENDENT KINASE (CDK)4 INHIBITORS AND THEIR USE FOR TREATING CANCER
(FR) INHIBITEURS DE KINASE DEPENDANTE DE CYCLINE (CDK)4 ET UTILISATION DE CEUX-CI DANS LE TRAITEMENT DE CANCER
Abstract:
(EN) Certain derivatives of acridones and benzothiadiazines have been found to have anti-cancer properties by virtue of their specific inhibition of the cyclin D dependant kinase CDK4. These molecules inhibit CDK4 activity more than they inhibit the activity of other such kinases (e.g. CDC2 and CDK2). This specificity results in an improved therapeutic index when used as drugs to treat susceptible cancers.
(FR) L'invention concerne certains dérivés d'acridones et de benzothiadiazines qui présentent des propriétés anticancéreuses en raison de leur capacité d'inhibition spécifique de la kinase dépendante de cycline D, CDK4. Les molécules en question inhibent l'activité de CDK4 davantage que l'activité d'autres kinases similaires (p. ex. CDC2 et CDK2). Cette spécificité permet d'obtenir un indice thérapeutique accru lorsque ces molécules sont utilisées comme médicaments pour traiter des cancers.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP0977738US6630464US20040006074JP2002506427 CA2288154AU1998074698